JILL SHEILS: Open Payments
NPI 1881021970 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$360 in 6 payments from 5 companies in 2025. Trend: 2023 $139 · 2024 $106 · 2025 $360
Food & beverage: $360
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $120 |
| Gen-Probe, Inc. | 1 | $97 |
| GlaxoSmithKline, LLC. | 1 | $86 |
| Merck Sharp & Dohme LLC | 2 | $40 |
| Genentech USA, Inc. | 1 | $16 |
Products named: LYNPARZA, APTIMA, KEYTRUDA, Tecentriq.
Industry payments across MD — which companies pay providers there.
